Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib plus bevacizumab for recurrent or metastatic ovarian cancer after prior PARP inhibitor therapy
ChiCTR2100047016Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pamiparib and bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Hunan Cancer Hospital. Primary endpoint: Objective response rate. Started Dec 2021; status: recruiting.
02
Drugs
pamiparibbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2100047016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047016.